KAZIA THERAPEUTICS LTD ADR reports a Return on Equity (ROE) of -109.18%.

What is KZIA's dividend yield?

KAZIA THERAPEUTICS LTD ADR offers a dividend yield of 0.00%.

What is KZIA's Deepscope Quality Score?

Deepscope rates KZIA's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy KZIA?

Deepscope's AI Timing Score for KZIA is 71 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does KZIA belong to?

KAZIA THERAPEUTICS LTD ADR is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

KZIA (NASDAQ) 株価分析 | KAZIA THERAPEUTICS LTD ADR

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-08 | FS: 2025-12-31)

KZIA

KAZIA THERAPEUTICS LTD ADR

US:NASDAQ STOCK Healthcare >> Biotechnology News 72

USD 11.40

0.41 (3.73%) Day Change

Watchlist Portfolio Compare Chart

0.00

D/E

-109.2%

ROE

-71.3%

ROA

0.00%

Div Yield

KAZIA THERAPEUTICS LTD ADR
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 11.40 Price 0.41 (3.73%) Day Change	NEWS SCORE: 72

KZIA, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) but テクニカルスコアは ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROAが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Deepscope 分析

44%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	72
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	11.40
PBV / Sector	2.71 / 4.75
Earning Per Share	-4.60

PE / Sector	N/A / 17.65
PEG or PE/Growth / Sector	N/A / 0.52
Average 1M Daily Value	2.47 M GREAT
Average 1W Daily Value	2.91 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

58%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-2,008.78 / 468.85
NPM Average (%) / Sector	-798,003.86 / -1,531.69
NPM Change Average (%) / Sector	1,331.65 / 5,028.65
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-71.34 / 31.69
ROA Average (%) / Sector	-135.91 / -353.18
ROA Change Average (%) / Sector	42.75 / 5,214.65 GREAT
ROE (%) / Sector	-109.18 / 10.58
ROE Average (%) / Sector	20.17 / 27.64 GOOD
ROE Change Average (%) / Sector	-95.95 / 2,048.88
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 3.97

登録情報

Analyze Date	2026-06-09 09:40:02
Symbol	KZIA
Name	KAZIA THERAPEUTICS LTD ADR
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	11.43 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	125.58 / 9,000.42

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Three International Towers, Sydney, NSW, Australia, 2000

Phone: 61 2 9472 4101

Website: https://www.kaziatherapeutics.com

Sector: Healthcare >> Biotechnology

Description: Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.